In 2025, we generated the first statewide estimate of the availability of pharmacist-initiated oral and long-acting injectable HIV PrEP in California community (retail) pharmacies. We estimated that fewer than 3% of community pharmacies offered these services. Despite the increasingly favorable policy environment in California, community pharmacists remain underutilized to advance HIV prevention efforts.
This policy brief presents findings from a mixed-methods study examining Los Angeles County pharmacy consumers’ perspectives on pharmacist-prescribed PrEP and PEP. Consumers reported high trust in pharmacists and strong willingness to use pharmacy-based HIV prevention services, but noted structural barriers such as long wait times, limited privacy, inconsistent continuity of care, and uncertainty around insurance […]
In this policy brief, we describe the impact of PBMs on community pharmacies, state and federal legislation to address PBM practices, and California pharmacists’ experience with current PBM drug reimbursement practices.
Doxycycline Post-exposure Prophylaxis better known as Doxy-PEP is a recently introduced sexually transmitted infection (STI) prevention option. Extending access to Doxy-PEP to more individuals within communities for whom it is recommended merits consideration.
Key updates to PrEP access include recent changes to state and federal law and policy. This summary includes changes likely to affect PrEP access in California.
A new CHPRC analysis evaluates the quality of the HIV-related information provided by ChatGPT and other popular chatbots powered by artificial intelligence (AI) and the extent to which these chatbots tailor their responses to address diverse HIV prevention needs.
Policy brief based on a study of seven California emergency departments (ED) implementing HIV Prevention Services (HPS) linkage programs. Three models for integrating HPS into the ED were identified and may serve as a guide for future protocol development.
The 340b program provides an important revenue source for many HIV clinics and facilities, but that revenue is dependent on drug pricing. The Inflation Reduction Act of 2022 introduced provisions to curb drug pricing. Our modeling suggests that 340b revenues generated from HIV-related prescriptions could decrease by as much as 50% if drug prices are […]
A new CHPRC analysis reveals California pharmacists’ preferences for implementing pharmacist-initiated PrEP for HIV prevention under Senate Bill 159. In a discrete choice experiment, pharmacists preferred implementation scenarios in which they play an active role in the PrEP provision process. However, their preferences around pharmacy workflow suggest that integrating new services requires increased workforce capacity.
This brief analyzes the impact of Orange County’s sterile syringe distribution program on client and community outcomes, and also assesses how its impact influenced risk of HIV and other outcomes among people who use drugs across the county.
